NPIL to trim ex-Pfizer site
NPIL Pharma last week told workers at its former Pfizer plant in Morpeth, UK that the company is considering hiving off jobs in a bid to maintain the site's viability.
NPIL Pharma last week told workers at its former Pfizer plant in Morpeth, UK that the company is considering hiving off jobs in a bid to maintain the site's viability.
Nanogen has decided to pull the plug on its microarray business after not finding any 'financially meaningful opportunities' for it, reducing staff by 20 per cent in the process.
Artel's third 'Extreme Pipetting' expedition went to Death Valley, US, to see the size of errors that dry heat would introduce to pipetted volumes and found they could be as high as 35 per cent.
An analyst report released yesterday identified AstraZeneca as being in 'serious trouble' and branded it as potentially the 'worst [large cap] performer in [the] entire sector' over the next eight years.
Applied Biosystems and BioTrove have signed a licensing and collaboration agreement to commercialise an analysis platform for high-throughput (HT) genotyping applications.
Canadian contract manufacturer PharmEng recently announced that its new specialised manufacturing facility in Nova Scotia is open for business.
As of next year Chinese pharmaceutical manufacturers will face a tougher time gaining good manufacturing practice (GMP) certification after the country's regulator signalled new and stricter standards were on the way.